Allott E.H.,Duke University |
Allott E.H.,Cancer Prevention Pharmaceuticals |
Allott E.H.,Veterans Affairs Medical Center Durham |
Howard L.E.,Duke University |
And 10 more authors.
Cancer Epidemiology Biomarkers and Prevention | Year: 2014
Background: Evidence for an association between total cholesterol, low- and high-density lipoproteins (LDL and HDL, respectively), triglycerides, and prostate cancer is conflicting. Given that prostate cancer and dyslipidemia affect large proportions of Western society, understanding these associations has public health importance. Methods: We conducted a retrospective cohort analysis of 843 radical prostatectomy (RP) patients who never used statins before surgery within the Shared Equal Access Regional Cancer Hospital (SEARCH) database. Multivariable Cox proportional hazards analysis was used to investigate the association between cholesterol, LDL, HDL, and triglycerides and biochemical recurrence risk. In secondary analysis, we explored these associations in patients with dyslipidemia, defined using National Cholesterol Education Program guidelines. Results: Elevated serum triglycerides were associated with increased risk of prostate cancer recurrence [HRper 10 mg/dl, 1.03; 95% confidence interval (CI), 1.01-1.05] but associations between total cholesterol, LDL and HDL, and recurrence risk were null. However, among men with dyslipidemia, each 10 mg/dl increase in cholesterol and HDL was associated with 9% increased recurrence risk (HR, 1.09; 95% CI, 1.01-1.17) and 39% reduced recurrence risk (HR, 0.61; 95% CI, 0.41-0.91), respectively. Conclusions: Elevated serum triglycerides were associated with increased risk of prostate cancer recurrence. Cholesterol, LDL, or HDL were not associated with recurrence risk among all men. However, among men with dyslipidemia, elevated cholesterol and HDL levels were associated with increased and decreased risk of recurrence, respectively. Impact: These findings, coupled with evidence that statin use is associated with reduced recurrence risk, suggest that lipid levels should be explored as a modifiable risk factor for prostate cancer recurrence. ©2014 AACR.
PubMed | Danish Cancer Society, Institute of Oncology, University of Houston, Institute For Humangenetik and 56 more.
Type: Journal Article | Journal: Journal of genetics and genome research | Year: 2016
Disruption in circadian gene expression, whether due to genetic variation or environmental factors (e.g., light at night, shiftwork), is associated with increased incidence of breast, prostate, gastrointestinal and hematologic cancers and gliomas. Circadian genes are highly expressed in the ovaries where they regulate ovulation; circadian disruption is associated with several ovarian cancer risk factors (e.g., endometriosis). However, no studies have examined variation in germline circadian genes as predictors of ovarian cancer risk and invasiveness. The goal of the current study was to examine single nucleotide polymorphisms (SNPs) in circadian genes
Allott E.H.,Duke University |
Howard L.E.,Duke University |
Howard L.E.,Cancer Prevention Pharmaceuticals |
Cooperberg M.R.,Veterans Affairs Medical Center |
And 8 more authors.
BJU International | Year: 2014
Objective To investigate the effect of statin use after radical prostatectomy (RP) on biochemical recurrence (BCR) in patients with prostate cancer who never received statins before RP. Patients and Methods We conducted a retrospective analysis of 1146 RP patients within the Shared Equal Access Regional Cancer Hospital (SEARCH) database. Multivariable Cox proportional hazards analyses were used to examine differences in risk of BCR between post-RP statin users vs nonusers. To account for varying start dates and duration of statin use during follow-up, post-RP statin use was treated as a time-dependent variable. In a secondary analysis, models were stratified by race to examine the association of post-RP statin use with BCR among black and non-black men. Results After adjusting for clinical and pathological characteristics, post-RP statin use was significantly associated with 36% reduced risk of BCR (hazard ratio [HR] 0.64, 95% confidence interval [CI] 0.47-0.87; P = 0.004). Post-RP statin use remained associated with reduced risk of BCR after adjusting for preoperative serum cholesterol levels. In secondary analysis, after stratification by race, this protective association was significant in non-black (HR 0.49, 95% CI 0.32-0.75; P = 0.001) but not black men (HR 0.82, 95% CI 0.53-1.28; P = 0.384). Conclusion In this retrospective cohort of men undergoing RP, post-RP statin use was significantly associated with reduced risk of BCR. Whether the association between post-RP statin use and BCR differs by race requires further study. Given these findings, coupled with other studies suggesting that statins may reduce risk of advanced prostate cancer, randomised controlled trials are warranted to formally test the hypothesis that statins slow prostate cancer progression. © 2014 The Authors. BJU International © 2014 BJU International.
News Article | December 9, 2016
— Neuroblastoma Pipeline Market Companies Involved in Therapeutics Development are Ability Pharmaceuticals SL, Acetylon Pharmaceuticals Inc, Advanced Accelerator Applications SA, Alissa Pharma, Ampio Pharmaceuticals Inc, APEIRON Biologics AG, AstraZeneca Plc, Bayer AG, Bellicum Pharmaceuticals Inc, Bexion Pharmaceuticals LLC, BioLineRx Ltd, Bionucleon Srl, Biotec Pharmacon ASA, Cancer Prevention Pharmaceuticals, Inc., Cebiotex SL, Celgene Corp, Cielo Therapeutics Inc, Cleveland BioLabs Inc, Codagenix, Inc., CorMedix Inc, Curis Inc, Cyclacel Pharmaceuticals Inc, DEKK-TEC Inc, EnGeneIC Ltd, Errant Gene Therapeutics LLC, F. Hoffmann-La Roche Ltd, GlaxoSmithKline Plc, Green Cross Cell Corp, Ignyta Inc, Incuron, LLC, Juno Therapeutics Inc, Kolltan Pharmaceuticals Inc, Lindis Biotech GmbH, MabVax Therapeutics Holdings Inc, MediaPharma srl, Merck & Co Inc, Merrimack Pharmaceuticals Inc, Morphogenesis Inc, Novartis AG, Novogen Ltd, OGD2 Pharma SAS, Pfizer Inc, Pharmacyclics Inc, Progenics Pharmaceuticals Inc, ProNAi Therapeutics Inc, Recombio SL, Ribomic Inc., Sapience Therapeutics Inc, Sareum Holdings Plc, Shionogi & Co Ltd, Syros Pharmaceuticals Inc and Tiltan Pharma Ltd. Neuroblastoma is the cancer of the nerve tissues and neural crest cells of adrenal glands, neck, chest or spinal cord, occurring predominantly in children. It usually begins in the adrenal glands further spreading to other parts of the body. The predisposing factors involved in neuroblastoma include genetic conditions. Symptoms include lump in abdomen or chest, weakness, bone pain, breathing problems, dark circles around the eyes and difficulty in movement. The condition may be diagnosed by X-ray imaging, CT scan, MRI, biopsy, urine test, etc. It may be controlled by chemotherapy, radiation therapy, stem cell transplants and medication such as monoclonal antibody regimens. This research provides comprehensive information on the therapeutics under development for Neuroblastoma (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Inquire more about this research report at http://www.reportsnreports.com/contacts/inquirybeforebuy.aspx?name=774100 The Neuroblastoma (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Neuroblastoma and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical and Discovery stages are 1, 1, 15, 15, 1, 43 and 4 respectively. Similarly, the Universities portfolio in Phase II, Phase I, Preclinical and Discovery stages comprises 8, 7, 9 and 4 molecules, respectively. Neuroblastoma (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Directs proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis. Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data. Buy a copy of this research report at http://www.reportsnreports.com/purchase.aspx?name=774100 • The pipeline guide provides a snapshot of the global therapeutic landscape of Neuroblastoma (Oncology). • The pipeline guide reviews pipeline therapeutics for Neuroblastoma (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources. • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages. • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities. • The pipeline guide reviews key companies involved in Neuroblastoma (Oncology) therapeutics and enlists all their major and minor projects. • The pipeline guide evaluates Neuroblastoma (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type. • The pipeline guide encapsulates all the dormant and discontinued pipeline projects. • The pipeline guide reviews latest news related to pipeline therapeutics for Neuroblastoma (Oncology) • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies. • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage. • Find and recognize significant and varied types of therapeutics under development for Neuroblastoma (Oncology). • Classify potential new clients or partners in the target demographic. • Develop tactical initiatives by understanding the focus areas of leading companies. • Plan mergers and acquisitions meritoriously by identifying key players and its most promising pipeline therapeutics. • Formulate corrective measures for pipeline projects by understanding Neuroblastoma (Oncology) pipeline depth and focus of Indication therapeutics. • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope. • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline. For more information, please visit http://www.reportsnreports.com/reports/774100-neuroblastoma-pipeline-review-h2-2016.html
Pollak K.I.,Cancer Prevention Pharmaceuticals |
Pollak K.I.,Duke University |
Lyna P.,Cancer Prevention Pharmaceuticals |
Bilheimer A.,Cancer Prevention Pharmaceuticals |
And 4 more authors.
Nicotine and Tobacco Research | Year: 2013
Introduction: Smoking during pregnancy causes multiple perinatal complications; yet, the smoking rate among pregnant women has remained relatively stagnant. Most interventions to help pregnant smokers quit or reduce their smoking are not easily disseminable. Innovative and disseminable interventions are needed. Methods: We recruited 31 pregnant smokers in their second trimester from prenatal clinics. We assessed feasibility, acceptability, and preliminary efficacy of an SMS text-based intervention in a 2-arm design. We compared SMS-delivered support messages to an intervention that provided support messages plus a scheduled gradual reduction (SGR) to help women reduce their smoking more than 3 weeks. We sent women in the SGR arm "alert texts" at times to instruct them to smoke. We asked women not to smoke unless they received an alert text. Results: Most women (86%) reported reading most or all of the texts. Women in both arms rated the program as helpful (M = 6, SD = 1 vs. M = 5, SD = 2, SGR vs. support only, respectively). Women in the SGR arm had a higher rate of biochemically validated 7-day point prevalence at the end of pregnancy 13.4% versus 7.5%. Of those still smoking, women reduced their smoking substantially with more reduction in the SGR arm (SGR arm: M = 16, SD = 11 vs. support messages only: M = 12, SD = 7). Conclusions: We developed an easily disseminable intervention that could possibly promote cessation and reduction among pregnant women with SMS texting ability. Women in this pilot were enthusiastic about the program, particularly those in the SGR arm. This program needs further examination. © The Author 2013. Published by Oxford University Press on behalf of the Society for Research on Nicotine and Tobacco. All rights reserved.
PubMed | University of Minnesota, Cancer Prevention Pharmaceuticals and National Cancer Institute
Type: | Journal: Cancer prevention research (Philadelphia, Pa.) | Year: 2016
Pioglitazone is a PPAR agonist commonly prescribed for the clinical treatment of diabetes. We sought to expand its use to lung cancer prevention in a benzo[a]pyrene (B[a]P) mouse model with direct lung delivery via inhalation. Initially we conducted inhalational toxicity experiments with 0, 15, 50, 150, and 450 g/kg body weight/day pioglitazone in 40 A/J mice. We examined the animals for any physical toxicity and bronchoalveolar lavage fluids for inflammatory and cytotoxicity markers. Doses up to and including 450 g/kg bw/day failed to demonstrate toxicity with aerosol pioglitazone. For chemoprevention experiments, A/J mice were randomized to treatment groups of inhaled doses of 0, 50, 150, or 450 g/kg bw/day pioglitazone one week or eight weeks after the last dose of B[a]P. For the early treatment group we found up to 32% decrease in lung adenoma formation with 450 g/kg bw/day pioglitazone. We repeated the treatments in a second late stage experiment and found up to 44% decreases in lung adenoma formation in doses of pioglitazone of 150 g/kg bw/day and 450 g/kg bw/day. Both the early and the late stage experiment demonstrated biologically relevant and statistically significant decreases in adenoma formation. We conclude aerosol pioglitazone is well tolerated in the A/J mouse model and a promising chemoprevention agent for the lower respiratory tract.